HRP20211590T1 - Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina - Google Patents
Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina Download PDFInfo
- Publication number
- HRP20211590T1 HRP20211590T1 HRP20211590TT HRP20211590T HRP20211590T1 HR P20211590 T1 HRP20211590 T1 HR P20211590T1 HR P20211590T T HRP20211590T T HR P20211590TT HR P20211590 T HRP20211590 T HR P20211590T HR P20211590 T1 HRP20211590 T1 HR P20211590T1
- Authority
- HR
- Croatia
- Prior art keywords
- nrc
- parts
- eudragit
- methacrylic acid
- formulation
- Prior art date
Links
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 18
- LCPGCGAJBOWMIP-UHFFFAOYSA-N n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3,5-bis(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LCPGCGAJBOWMIP-UHFFFAOYSA-N 0.000 claims 16
- 238000009472 formulation Methods 0.000 claims 14
- 229920003135 Eudragit® L 100-55 Polymers 0.000 claims 8
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims 8
- 229920003141 Eudragit® S 100 Polymers 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 229920000831 ionic polymer Polymers 0.000 claims 6
- 239000011159 matrix material Substances 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 5
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 4
- 229920002125 Sokalan® Polymers 0.000 claims 4
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000007962 solid dispersion Substances 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims 3
- 229960003943 hypromellose Drugs 0.000 claims 3
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 3
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000012296 anti-solvent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920001249 ethyl cellulose Polymers 0.000 claims 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims 2
- 238000001556 precipitation Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- -1 defoamers Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000009474 hot melt extrusion Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 239000002244 precipitate Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000935 solvent evaporation Methods 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000002562 thickening agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN6951CH2015 | 2015-12-18 | ||
| PCT/IN2016/050035 WO2017103941A1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
| EP16875074.3A EP3389633B1 (en) | 2015-12-18 | 2016-01-30 | Pharmaceutical compositions comprising phenylaminopyrimidine derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211590T1 true HRP20211590T1 (hr) | 2022-01-07 |
Family
ID=59055898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211590TT HRP20211590T1 (hr) | 2015-12-18 | 2016-01-30 | Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina |
Country Status (33)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12084472B2 (en) | 2015-12-18 | 2024-09-10 | Ardelyx, Inc. | Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物 |
| CZ2017821A3 (cs) * | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
| CN112118830B (zh) * | 2018-05-14 | 2023-11-10 | 比利时胶囊公司 | 高活性剂载量的固体剂型 |
| JP7368548B2 (ja) * | 2021-07-02 | 2023-10-24 | 昊運股▲フン▼有限公司 | 薬学的組成物及びその使用 |
| CN115583634B (zh) * | 2022-09-21 | 2023-06-06 | 广东工业大学 | 一种碳氮聚合物材料的制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002241268A (ja) * | 2000-12-11 | 2002-08-28 | Takeda Chem Ind Ltd | 水溶解性が改善された医薬組成物 |
| HRP20070146B1 (hr) | 2004-09-09 | 2015-12-04 | Natco Pharma Limited | Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze |
| US8067422B2 (en) | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| WO2012002547A1 (ja) * | 2010-07-02 | 2012-01-05 | 富士化学工業株式会社 | ボセンタン固体分散体 |
| GB2488788B (en) * | 2011-03-07 | 2013-07-10 | Natco Pharma Ltd | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| CN102836159B (zh) * | 2011-06-24 | 2014-12-10 | 南京圣和药业股份有限公司 | 达沙替尼分散体及其制备方法和其在片剂中的应用 |
| JP2017500343A (ja) * | 2013-12-20 | 2017-01-05 | フォスフォレックス，インコーポレーテッド | インジルビン固体分散体組成物 |
-
2016
- 2016-01-30 MA MA44079A patent/MA44079B1/fr unknown
- 2016-01-30 KR KR1020187020546A patent/KR20180102584A/ko not_active Ceased
- 2016-01-30 HK HK18113869.1A patent/HK1254573A1/zh unknown
- 2016-01-30 GE GEAP201614833A patent/GEP20207176B/en unknown
- 2016-01-30 UA UAA201806892A patent/UA122592C2/uk unknown
- 2016-01-30 JP JP2018532262A patent/JP6896738B2/ja not_active Expired - Fee Related
- 2016-01-30 EP EP16875074.3A patent/EP3389633B1/en active Active
- 2016-01-30 HR HRP20211590TT patent/HRP20211590T1/hr unknown
- 2016-01-30 EA EA201891443A patent/EA036513B1/ru unknown
- 2016-01-30 HU HUE16875074A patent/HUE056269T2/hu unknown
- 2016-01-30 SG SG11201805142RA patent/SG11201805142RA/en unknown
- 2016-01-30 BR BR112018012458A patent/BR112018012458A2/pt not_active IP Right Cessation
- 2016-01-30 CA CA3008634A patent/CA3008634A1/en not_active Abandoned
- 2016-01-30 AU AU2016373574A patent/AU2016373574B2/en not_active Expired - Fee Related
- 2016-01-30 US US16/062,320 patent/US10383872B2/en not_active Expired - Fee Related
- 2016-01-30 SM SM20210583T patent/SMT202100583T1/it unknown
- 2016-01-30 GB GB1811142.7A patent/GB2564262A/en not_active Withdrawn
- 2016-01-30 WO PCT/IN2016/050035 patent/WO2017103941A1/en not_active Ceased
- 2016-01-30 ES ES16875074T patent/ES2881883T3/es active Active
- 2016-01-30 DK DK16875074.3T patent/DK3389633T3/da active
- 2016-01-30 MX MX2018007281A patent/MX374725B/es active IP Right Grant
- 2016-01-30 SI SI201631339T patent/SI3389633T1/sl unknown
- 2016-01-30 LT LTEPPCT/IN2016/050035T patent/LT3389633T/lt unknown
- 2016-01-30 PL PL16875074T patent/PL3389633T3/pl unknown
- 2016-01-30 PT PT168750743T patent/PT3389633T/pt unknown
- 2016-01-30 CN CN201680079960.9A patent/CN108495620B/zh not_active Expired - Fee Related
- 2016-01-30 RS RS20211232A patent/RS62422B1/sr unknown
-
2018
- 2018-06-14 CL CL2018001590A patent/CL2018001590A1/es unknown
- 2018-06-17 IL IL260085A patent/IL260085B/en unknown
- 2018-06-18 PH PH12018501292A patent/PH12018501292A1/en unknown
- 2018-06-22 ZA ZA2018/04203A patent/ZA201804203B/en unknown
- 2018-07-09 CO CONC2018/0007112A patent/CO2018007112A2/es unknown
-
2020
- 2020-12-03 JP JP2020201322A patent/JP2021059551A/ja not_active Withdrawn
-
2021
- 2021-10-13 CY CY20211100881T patent/CY1124580T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211590T1 (hr) | Farmaceutske kompozicije koje sadrže derivat fenilaminopirimidina | |
| JP6073043B2 (ja) | 医薬品適用のための熱−動力学的混合 | |
| ES2922637T3 (es) | Forma de dosificación farmacéutica sólida de inhibidor de PARP y aplicación de forma de dosificación farmacéutica sólida de inhibidor de PARP | |
| CN103998037B (zh) | 对高熔点疏水性化合物具有改进的生物利用度的药物组合物 | |
| US20140350027A1 (en) | Pharmaceutical Compositions Comprising Imatinib and a Release Retardant | |
| JP6537147B2 (ja) | 固体分散体 | |
| HRP20211423T1 (hr) | Formulacije enzalutamida | |
| HRP20180068T1 (hr) | Formulacije lijeka s produljenim oslobađanjem | |
| ES2351947T3 (es) | Formulaciones orales de liberacion controlada de un inhibidor de la enzima convertidora de interleucina-1-beta. | |
| JP6324930B2 (ja) | フェニルアラニン誘導体を含有する医薬製剤 | |
| ME02687B (me) | Dozni oblik otporan na promene | |
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| AR063259A1 (es) | Formas solidas de dosificacion farmaceuticas que comprenden compuestos microincluidos en polimeros ionicos insolubles en agua | |
| AU2015257658A1 (en) | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds | |
| ES2721849T3 (es) | Forma oral sólida dotada de un doble perfil de liberación que comprende multipartículas | |
| JP2017512194A5 (enExample) | ||
| AR102571A1 (es) | Unidad de dispositivo con medicamento conteniendo quinagolida para uso en endometriosis, método | |
| HRP20161794T1 (hr) | Novi terapijski pristupi za liječenje neuroinflamatornih stanja | |
| FI3601277T3 (fi) | Farmaseuttinen formulaatio | |
| WO2025214247A1 (zh) | 恩扎卢胺药物组合物及其制备方法和用途 | |
| WO2014180912A1 (en) | Modified release formulations of lacosamide | |
| ES2529443T3 (es) | Composición farmacéutica para tratar infecciones del HCV | |
| Pinto et al. | Cellulose ethers for extrusion applications | |
| HRP20220309T1 (hr) | Nove oralne formulacije belinostata | |
| KR101352867B1 (ko) | 동물용 복합항생제 조성물 |